An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Inclusion Criteria

• •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 1
• •Histologically confirmed Stage IV, or Recurrent NSCLC with no prior systemic anticancer therapy
• •Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per response evaluation criteria in solid tumors version (RECIST) 1.1 criteria
• •PD-L1+ on immunohistochemistry testing performed by central lab
• •Men and women, ages ≥ 18 years of age